Duplication of subcytoband IIE2 of chromosome II is regularly associated with accelerated tumor development in v-abl/myc-induced mouse plasmacytomas

Genes and Cancer

Volumn 1, Issue 8, 2010, Pages 847-858

  Wiener, Francis ^a,b   Schmälter, Ann Kristin ^a   Mowat, Michael R A ^a   Mai, Sabine ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chromosome II; Mouse plasmacytoma; V abl myc

Indexed keywords

PRISTANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CHROMOSOME 11; CHROMOSOME DUPLICATION; CONGENIC STRAIN; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; MALE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE MYC; ONCOGENE V ABL; PLASMACYTOMA; PRIORITY JOURNAL; RISK FACTOR; SUBCYTOBAND II E2; TELOMERE; TRISOMY; TUMOR GROWTH; X CHROMOSOME;

RATTUS;

EID: 79251527992     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910382897     Document Type: Article

References (52)

1. Klein G. Specific chromosomal translocation and genesis of B-cellderived tumors in mice and men. Cell. 1983;32:311-6.
2. Adams JM, Gerondakis S, Webb E, Corcoran LM, Cory S. Cellular myc oncogene is altered by chromosome translocation to an immunoglobulin locus in murine plasmacytomas and is rearranged similarly in human Burkitt lymphomas. Proc Natl Acad Sci U S A. 1983;80(7):1982-6.
3. Pear WS, Wahlström G, Nelson SF, et al. 6;7 chromosomal translocation in spontaneously arising rat immunocytomas: evidence for c-myc breakpoint clustering and correlation between isotypic expression and the c-myc target. Mol Cell Biol. 1988;8(1):441-51.
4. Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res. 1986;47:189-234.
5. Potter M, Wiener F. Plasmacytoma genes in mice: model of neoplastic development dependent upon chromosomal translocation. Carcinogenesis. 1992;13:1681-97.
6. Park ES, Shaughnessy JD, Gupta S, et al. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics. 2007;8:302.
7. Largaespada DA, Kaehler DA, Mishak H, et al. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas. Oncogene. 1992;7(4):811-9.
8. Weissinger EM, Mischak H, Goodnight J, Davidson WF, Mushinski JF. Addition of constitutive c-myc expression to Abelson murine leukemia virus changes the phenotype of the cells transformed by the virus from pre-B-cell lymphomas to plasmacytomas. Mol Cell Biol. 1993;13(4):2578-85.
9. Kerr LD. Arrested development: understanding v-abl. BioEssays. 1994;7:453-5.
10. Chen Y-Y, Wand LC, Huang MS, Rosenberg N. An active v-abl protein tyrosine kinase blocks immunoglobulin light-chain gene rearrangement. Genes Dev. 1994;8:688-97.
11. Jacobsen EA, Ananieva O, Brown ML, Chang Y. Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene. J Immunol. 2006;176:6831-8.
12. Risser R, Potter M, Rowe WP. Abelson virus-induced lymphomagenesis in mice. J Exp Med. 1978;148(3):714-26.
13. Sugiyama H, Weber G, Silva S, Babonits M, Wiener F, Klein G. Studies on the accelerating role of Abelson leukemia virus in murine plasmacytoma development: in vitro infection of spleen cells generated donor type tumors after transfer to pristane treated BALB/c mice. Int J Cancer. 1989;44:348-53.
14. Sugiyama H, Silva S, Wang Y, et al. Abelson murine leukemia virus transforms preneoplastic Emu myc transgene carrying cells of the B lymphocyte lineage into plasmablastic tumors. Int J Cancer. 1990;46:845-52.
15. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046):533-8.
16. Alexander WS, Adams JM, Cory S. Oncogene cooperation in lymphocyte transformation: malignant conversion of E mu-myc transgenic pre-B cells in vitro is enhanced by v-H-ras or v-raf but not v-abl. Mol Cell Biol. 1989;9(1):67-73.
17. Rosenbaum H, Harris AW, Bath ML, et al. An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J. 1990;9(3):897-905.
18. Silva S, Babonits M, Wiener F, Klein G. Plasmacytoma induction in radiochimeras. Int J Cancer. 1989;44:337-43.
19. Silva S, Sugiyama H, Babonits M, Wiener F, Klein G. Differential susceptibility of BALB/c and DBA/2 cells to plasmacytoma induction in reciprocal chimeras. Int J Cancer. 1991;49:224-48.
20. Wiener F, Silva S, Sugiyama H, Babonits M, Klein G. The "missing" mouse plasmacytoma (MPC) associated translocation T(15;16) occurs repeatedly in new MPC induction system. Genes Chromosomes Cancer. 1990;2:36-43.
21. Shore SK, Ramana VT, Reddy P. Transforming pathways activated by the v-Abl tyrosinase. Oncogene. 2002;21:8568-76.
22. Ohno S, Babonits M, Wiener F, et al. Non-random chromosome changes involving Ig gene chromosomes (Nos.12 and 6) in pristane induced mouse plasmacytoma. Cell. 1979;16:1001-7.
23. Wiener F, Babonits M, Spira J, Klein G, Potter M. Cytogenetic studies on the IgA/lambda producing murine plasmacytomas: regular occurrence of T(12;15) translocation. Somatic Cell Genet. 1980;6:731-8.
24. Ohno S, Migita S, Wiener F, et al. Chromosomal translocation activating myc sequences and transduction of v-abl are critical events in the rapid induction in plasmacytomas by pristane and Abelson virus. J Exp Med. 1984;159:1762-77.
25. Wiener F, Coleman A, Mock BA, Potter M. Non random chromosomal change (trisomy 11) in murine plasmacytomas induced by an ABL MYC retrovirus. Cancer Res. 1995;55:1181-6.
26. Potter M, Mushinski JF, Mushinski EB, et al. Avian v-myc replaces chromosomal translocation in murine plasmacytomagenesis. Science. 1987;235(4790):787-9.
27. Searle AG, Ford CE, Ewns EP, et al. The induction of translocation in mouse spermatozoa. I: kinetics of dose response with acute irradiation. Mutat Res. 1974;22:157-74.
28. Searle AG, Beechey CV, Evans EP, Kirk M. Two new X autosome translocation in the mouse. Cytogen Cell Genet. 1983;35:279-92.
29. Johannes C, Chudoba I, Obe G. Analysis of X-ray-induced aberrations in human chromosome 5 using high-resolution multicolour banding FISH (mBAND). Chromosome Res. 1999;7(8):625-33.
30. Klein G, Ohno S, Rosenberg N, Wiener F, Baltimore D. Cytogenetic studies on Abelson virus induced mouse leukemias. Int J Cancer. 1980;25:805-11.
31. Aubert D, Heuze F, Diez E, Jotereau F, Berger R. Cytogenetics of Abelson virus-induced malignant lymphoma cell lines in the mouse. Cancer Genet Cytogenet. 1987;28(1):119-25.
32. Dofuku R, Biedler JL, Spengler BA, Old LJ. Trisomy of chromosome 15 in spontaneous leukemia of AKR mice. Proc Nat Acad Sci U S A. 1975;72(4):1515-7.
33. Wiener F, Ohno S, Spira J, Ghera NNH, Klein G. Chromosomal changes (trisomy 15 and 17) associated with tumor progression in leukemias induced by radiation leukemia virus (RadLV). J Natl Cancer Inst. 1978;61:227-37.
34. Wiener F, Spira J, Ohno S, Ghera NH, Klein G. Chromosome changes (trisomy 15) in murine T cell leukemia induced with by 7,12 Dimethylbenz(a)anthracene (DMBA). Int J Cancer. 1978;22:447-53.
35. Wiener F, Babonits M, Spira J, et al. Chromosome 15 trisomy in spontaneous and carcinogen induced lymphomas of B cell origin. J Natl Cancer Inst. 1981;27:51-8.
36. Benedek K, Chudoba I, Klein G, Wiener F, Mai S. Rearrangements of the telomeric region of mouse chromosome 11 in Pre-B ABL/MYC cells revealed by mBANDing, spectral karyotyping, and fluorescence in-situ hybridization with a subtelomeric probe. Chromosome Res. 2004;12:777-85.
37. Turhan N, Yürür-Kutlay N, Topcuoglu P, et al. Translocation (13;17) (q14;q25) as a novel chromosomal abnormality in acute myeloid leukemia-M4. Leuk Res. 2006;30(7):903-5.
38. Taki T, Ohnishi H, Shinohara K, et al. AF17q25, a putative septin family gene, fuses the MLL gene in acute myeloid leukemia with t(11;17) (q23;q25). Cancer Res. 1999;59(17):4261-5.
39. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107(2):76-94.
40. Montagna C, Lyu MS, Hunter K, et al. The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. Cancer Res. 2003;63(9):2179-87.
41. Russell SE, McIlhatton MA, Burrows JF, et al. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res. 2000;60(17):4729-34.
42. Langan JE, Cole CG, Huckle EJ, et al. Novel microsatellite markers and single nucleotide polymorphisms refine the tylosis with oesophageal cancer (TOC) minimal region on 17q25 to 42.5 kb: sequencing does not identify the causative gene. Hum Genet. 2004;114(6):534-40.
43. Burrows JF, Chanduloy S, McIlhatton MA, et al. Altered expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol. 2003;201(4):581-8.
44. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res Treat. 2009;113(2):239-49.
45. Thomassen M, Tan Q, Kruse TA.Erratum in: Breast Cancer Res Treat. 2009;113(2):251-2.
46. Hwang KT, Han W, Cho J, et al. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Int J Cancer. 2008;123(8):1807-15.
47. Atiye J, Wolf M, Kaur S, et al. Gene amplifications in osteosarcoma- CGH microarray analysis. Genes Chromosomes Cancer. 2005;42(2):158-63.
48. Lastowska M, Chung Y-J, Ching NC, et al. Regions syntenic to human 17q are gained in mouse and rat neuroblastoma. Genes Chromosomes Cancer. 2004;40:158-63.
49. Koelsch BU, Rajewsky MF, Kindler-Röhrborn A. A 6-Mb contigbased comparative gene and linkage map of the rat schwannoma tumor suppressor region at 10q32.3. Genomics. 2005;85(3):322-9.
50. Mouse Book MRC Harwell. Available from: www.mousebook.org/index.php
51. Mai S, Wiener F. Murine FISH. In: Beatty B, Mai S, Squire J, editors. A practical approach. Oxford: Oxford University Press; 2002. p. 55-76.
52. Lyon MF. New rules for nomenclature of genes, chromosome anomalies and inbred strains. Mouse News Lett. 1979;61:4-16.